|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquired
|
gptkb:Baxter_International
|
|
gptkbp:acquisition
|
gptkb:collaboration
gptkb:2007
|
|
gptkbp:awards
|
industry recognition
|
|
gptkbp:brand
|
well-known in the industry
|
|
gptkbp:certification
|
FDA approved
|
|
gptkbp:clinical_trial
|
ongoing
collaborative studies
phases I, II, and III
|
|
gptkbp:community_involvement
|
healthcare initiatives
|
|
gptkbp:competitors
|
gptkb:CSL_Behring
gptkb:Grifols
gptkb:Octapharma
|
|
gptkbp:customer_base
|
hospitals and clinics
|
|
gptkbp:customer_support
|
dedicated service team
|
|
gptkbp:employees
|
over 500
|
|
gptkbp:employs
|
hundreds of people
|
|
gptkbp:financial_performance
|
strong growth
|
|
gptkbp:focus
|
therapeutics
|
|
gptkbp:focus_area
|
plasma-derived therapies
|
|
gptkbp:founded
|
gptkb:1960
|
|
gptkbp:founder
|
gptkb:Dr._William_Cutter
|
|
gptkbp:global_presence
|
international markets
|
|
gptkbp:grants
|
funding for innovative projects
|
|
gptkbp:headquarters
|
gptkb:Berkeley,_California
|
|
gptkbp:historical_event
|
established in 1960
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cutter Laboratories
|
|
gptkbp:industry
|
healthcare
|
|
gptkbp:innovation
|
focus on R& D
|
|
gptkbp:invention
|
numerous patents
|
|
gptkbp:key_people
|
gptkb:Dr._William_Cutter
|
|
gptkbp:known_for
|
hemophilia treatments
|
|
gptkbp:market
|
consumer insights
biotechnology market
|
|
gptkbp:marketing_strategy
|
expansion into new markets
|
|
gptkbp:mission
|
improving patient health
|
|
gptkbp:operates_in
|
gptkb:United_States
|
|
gptkbp:parent_company
|
gptkb:Baxter_International
|
|
gptkbp:partnerships
|
government agencies
academic institutions
various healthcare organizations
research organizations
|
|
gptkbp:product_line
|
therapeutic proteins
diagnostic products
vaccines for infectious diseases
|
|
gptkbp:products
|
cutting-edge technology
blood plasma products
|
|
gptkbp:region
|
gptkb:North_America
|
|
gptkbp:regulatory_compliance
|
strict adherence to regulations
|
|
gptkbp:research_areas
|
immunology
Berkeley facility
|
|
gptkbp:research_focus
|
vaccine development
|
|
gptkbp:revenue
|
millions of dollars
|
|
gptkbp:safety_features
|
high standards
|
|
gptkbp:services
|
biopharmaceuticals
|
|
gptkbp:social_responsibility
|
community health programs
|
|
gptkbp:specializes_in
|
vaccines
|
|
gptkbp:subsidiary
|
gptkb:Cutter_Bio_Science
|
|
gptkbp:supply_chain
|
efficient logistics
global suppliers
|
|
gptkbp:sustainability
|
environmental responsibility
|
|
gptkbp:type
|
private company
|
|
gptkbp:values
|
gptkb:collaboration
gptkb:accountability
innovation
integrity
excellence
|
|
gptkbp:vision
|
leading in biopharmaceutical innovation
|
|
gptkbp:website
|
www.cutter.com
|
|
gptkbp:bfsParent
|
gptkb:The_Cutter_Incident
|
|
gptkbp:bfsLayer
|
6
|